Galactosemia is autosomal recessive. A child must inherit two copies of the mutated gene, one from each parent, to develop the condition. A single copy makes someone a carrier but does not cause the disease.
What Autosomal Recessive Means
Every person carries two copies of each gene, one inherited from each parent. In autosomal recessive conditions like galactosemia, both copies need to be mutated for the disease to appear. If only one copy is mutated, the working copy produces enough enzyme to process galactose normally. That person is a carrier: healthy, with no symptoms, but capable of passing the mutation to their children.
Carriers of a galactosemia mutation have about 50% of normal enzyme activity. That’s more than enough to break down galactose without any clinical or biochemical problems. The condition only develops when enzyme activity drops to near zero, which happens when both gene copies are non-functional.
Risk When Both Parents Are Carriers
When two carriers have a child, the math follows a predictable pattern with each pregnancy: a 25% chance the child inherits two mutated copies and has galactosemia, a 50% chance the child inherits one mutated copy and is a carrier like the parents, and a 25% chance the child inherits no mutations at all. These odds reset with every pregnancy. Having one affected child doesn’t change the probability for the next.
Because carriers show no symptoms, most parents don’t know they carry the mutation until a child is diagnosed. Classic galactosemia occurs in roughly 1 in 16,000 to 1 in 50,000 live births in Western countries, which gives a sense of how common carrier status is in the general population.
Three Types, Same Inheritance Pattern
All three types of galactosemia follow autosomal recessive inheritance, but they involve different genes. Type I, the classic and most severe form, results from mutations in the GALT gene. This gene produces the primary enzyme responsible for converting galactose into glucose and other usable molecules. When both copies are mutated, the enzyme is almost completely absent.
Type II involves a different gene (GALK1) that produces an enzyme playing a supportive role in galactose metabolism. Type III stems from yet another gene (GALE) with a similarly supportive function. Types II and III are generally less severe than classic galactosemia, but all three require two mutated copies of the relevant gene to cause disease.
The Duarte Variant
There’s an important middle ground called the Duarte variant. Someone who inherits one Duarte variant and one classic galactosemia mutation ends up with reduced but not absent enzyme activity. People who are homozygous for the Duarte variant (carrying two Duarte copies) have about 50% of normal enzyme activity, similar to a carrier of classic galactosemia. This level of enzyme function is sufficient, and these individuals don’t develop clinical symptoms. The Duarte variant often shows up on newborn screening as mildly low enzyme activity, which can cause initial concern but typically doesn’t require the same strict dietary restrictions as classic galactosemia.
How Newborn Screening Catches It
In the United States, all states screen newborns for classic galactosemia within days of birth using a heel-prick blood sample. The screening measures how much GALT enzyme activity is present in the blood. Some states also measure total galactose levels. Babies with low GALT activity, with or without elevated galactose, are flagged for follow-up testing.
Early detection matters enormously. Classic galactosemia causes serious harm quickly once a newborn begins drinking breast milk or standard formula, both of which contain lactose that breaks down into galactose. Without prompt intervention, galactose accumulates and damages the liver, brain, and other organs within days to weeks.
Dietary Management and Long-Term Outlook
Treatment centers on removing galactose from the diet, starting immediately after diagnosis. Affected infants are switched to soy-based or other galactose-free formulas and must avoid milk, dairy products, and other foods containing galactose for life. This dietary restriction is effective at preventing the acute, life-threatening complications of the disease.
However, even with early detection and lifelong dietary management, many people with classic galactosemia experience long-term developmental challenges. These can include difficulties with speech, language, motor skills, cognitive function, and psychosocial well-being. A large study found that the majority of these complications do not worsen over time: fewer than 10% of patients reported worsening symptoms in any category, suggesting these are stable developmental differences rather than progressive decline. Still, the existence of these complications despite treatment underscores that galactosemia management reduces harm but doesn’t fully eliminate it.